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tion of dementia, this article considers whether lowering plasma homocysteine by B-vitamin supple-
mentation is one of the top priority and cost-effective treatments.
Method: A decision model was constructed to calculate the lifetime costs and quality-adjusted life
years (QALYs) of providing B-vitamin treatment to people in the United Kingdom over 60 years with
high levels (.13 mmol/L) of plasma homocysteine, which was compared to the lifetime costs and
outcomes of not providing them with the treatment.
Results: TreatmentwithB-vitaminswill save£60,021perQALYgained and so is highly cost-effective.
Discussion: We anticipate that this provocative finding will be debated by scientists, clinicians, and
policy makers and eventually be tested in future clinical trials.
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Dementia is an increasing threat to population health
because of its association with the aging of the population,
reduced quality of life, and premature mortality. It also poses
substantial financial demands on the economy due to the
increasing requirement for health and social care for people
with dementia as well as substantial need for informal care.
A recent report estimated the overall annual costs of demen-
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commons.org/licenses/by-nc-nd/4.0/).which only £4.3 billion is spent on health care [1]. Consid-
ering also that a third of people in the UK born in 2015
will develop dementia in their lifetime [2] and the lack of
an effective treatment for dementia [3], focusing on preven-
tion of dementia certainly deserves to be high in health pol-
icy agenda [4]. Decision-makers urgently need evidence
about the cost-effectiveness of the potential prevention
strategies [3].
However, limited mental health budgets and underspend-
ing in research on dementia compared with public and pri-
vate funds for research in cancer and cardiovascular
disease [5] limits the possibility of providing evidence for
all available prevention strategies in the short term. There-
fore, we need to prioritize resources on strategies that would
be the most worthwhile to focus future research on.
This article argues that B-vitamins are one of the top pri-
ority preventive treatments and aims to stimulate debate on
this argument by investigating whether B-vitamins are
potentially a cost-effective treatment, taking the situation
in the United Kingdom as an example.imer’s Association. This is an open access article under the CC BY-NC-ND
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Strategies for prevention, with the aim of decreasing the
prevalence of dementia, are based on monitoring and con-
trolling risk factors associated with dementia. These risk
factors are broadly categorized as age, genetic factors,
vascular and metabolic factors, lifestyle factors, diet and
nutritional factors, and other factors (e.g., depression, occu-
pational exposure) [3]. Among modifiable risk factors,
high-plasma total homocysteine (tHcy) level, lower educa-
tion attainment, and decreased physical activity were found
in a recent meta-analysis to be particularly strong predictors
of dementia [6]. Among these three strong predictors, tHcy
is the only chemical risk factor biomarker for cognitive
impairment and dementia [7]. Plasma tHcy concentrations
can be screened relatively easily and are readily lowered
by high-dose B vitamin supplementation [8]. Although
there are no trials to test the effect of lowering tHcy on
the incidence of dementia, a recent literature review showed
that trials with high-risk subjects have shown positive re-
sults of B-vitamin treatment in modifying the dementia dis-
ease process [7]. The FACIT trial showed that folic acid
supplementation could lower tHcy levels and delay age-
related cognitive decline in people aged 50–70 years with
high tHcy [9]. B-vitamin supplementation (a combination
of vitamin B6, vitamin B12, and folic acid) in the VITA-
COG trial has been shown to be effective as a disease-
modifying intervention in elderly with mild cognitive
impairment by reducing elevated tHcy levels, by slowing
whole brain atrophy [10] and regional brain atrophy [11],
and by slowing further cognitive decline [12]. The VITAL
trial showed a positive effect of B-vitamin treatment in
slowing cognitive decline on the Alzheimer Disease Assess-
ment Scale (ADAS-cog) [13] and on the Mini-Mental State
Examination (Fig. 7 in ref. [7]) for patients with mild AD.
B-vitamin supplements are available over-the-counter at
very low cost, in contrast to long-term more expensive stra-
tegies that aim to increase education attainment or physical
activity. B-vitamins, in the doses required, are considered
without harm to health. Hence, we hypothesize that
B-vitamin treatment has great potential to be cost-
effective, and so, we performed a simulation exercise to
investigate the potential cost-effectiveness of screening
people above the age of 60 years in the United Kingdom
and treating those with high levels of tHcy with B-vitamins.
The aim of this exercise was to provoke discussion about
cost-effective prevention of dementia and to stimulate
further clinical trials on the impact of lowering tHcy levels.2. Methods
To achieve the aim of the study, an explorative cost-
effectiveness analysis was undertaken by following NICE
recommendations for modeling and exploring uncertainty
in technology appraisals [14]. A lifetime time-horizon was
chosen in the analysis.2.1. Stochastic decision model
A stochastic decision model was constructed in Excel to
calculate the lifetime costs and outcomes of providing B-
vitamin treatment to people over 60 years with high levels
of tHcy, which was compared to the lifetime costs and out-
comes of not providing them with the treatment. The model
performed 10,000 iterations of all cost and effect parameters
using prespecified distributions of input parameters and
recording incremental costs and incremental quality-
adjusted life years (QALYs) from each iteration. Input pa-
rameters were related to the target population, treatment ef-
fect, costs, and health outcomes (life years and QALYs). The
incremental cost-effectiveness ratios (ICERs) were ex-
pressed as costs per QALY per treated person. The ICERs
were plotted on cost-effectiveness planes to display the un-
certainty in the results.
To populate the model, we used information from the
literature about the potential target population, treatment ef-
fect and costs of dementia as well as life expectancy and
quality of life of people over 60 years with and without de-
mentia. When there was no information available in the liter-
ature, we made assumptions based on expert opinions.
Furthermore, we used a relative standard error (i.e., standard
error as percentage of the mean estimate) of 30% when stan-
dard errors of the mean were not available. This is consid-
ered to be the maximum relative standard error allowing
for the report of a mean estimate. As an exception, for the
utility (or else quality of life) parameters (with and without
dementia), we used a relative standard error of 5% to restrict
the cases where people attach higher utility to having de-
mentia than not to having it, which is hardly realistic. Vita-
mins were assumed not to have negative impact on health
and therefore, incremental QALYs can theoretically never
become negative in our analysis. However, we allowed in-
cremental QALYs to take negative values to incorporate
extreme, close to unrealistic, cases in which treated patients
would value the disutility of taking vitamins every day dur-
ing the gained dementia-free years higher than having de-
mentia in the same period. Moreover, the model assumed
that people would receive B-vitamin treatment until demen-
tia onset or death.2.2. Parameters used in the model
The parameters used in the decision model are listed in
Table 1 and discussed in detail in the subsequent sections.
We defined a “high tHcy concentration” as . 13 mmol/L,
as used by Pfeiffer et al [15]. The VITACOG trial showed
that elderly people with mild cognitive impairment who
had concentrations of tHcy above 13 mmol/L responded to
B-vitamin treatment with a 53% reduction in the rate of
whole brain atrophy [10], a 9-fold slowing of the rate of at-
rophy of specific brain regions involved in Alzheimer’s dis-
ease [11], and a measurable clinical improvement as
assessed by the Clinical Dementia Rating score [12].
Table 1
Parameters used in the decision model
Code Variable Value Standard error Source
Target population
A Population .60 y in the United Kingdom (2014) 14,918,400 Office of National Statistics, 2015
B % of people .60 y with high level tHcy 0.09 0.02 Pfeiffer et al. [15]
C Population attributable risk percentage (PAR%) 0.2170 0.05 Beydoun et al. [6]
D Dementia prevalence over 60 y (2014) 831,000 43,878 Lewis et al. [16]
E People in UK with high tHcy in UK in 2014 1,293,425 Calculated by authors based on A*B
F People at risk to develop dementia due to high tHcy 280,673 Calculated by authors based on C*D
G People over 60 y who will develop dementia due to
high tHcy
60,906 Calculated by authors based on C*F
Treatment
H Delay to develop dementia due to treatment, y 0.91 0.38 Oulhaj et al. [17]
I Adherence to vitamin B treatment 0.78 0.23 Smith et al. [10]
J Elapsed years from tHcy screening to dementia 10.16 3.05 Calculated based on Prince et al. [1] and Statistics
OoN [18]
K Vitamin effect on delaying dementia, y 0.71
Health outcomes
L Mean life years with dementia .60 y 5.96 Calculated based on Lewis [2] and Statistics OoN
[18,19]
M Mean life years without dementia .60 y 14.91 Calculated based on Lewis [2] and Statistics OoN
[18,19]
N Mean QALYs with dementia .60 y 3.19 Calculated based on Lewis [2], Statistics OoN
[18,19], and Knott [20]
O Mean QALYs without dementia .60 y 12.52 Calculated based on Lewis [2], Statistics OoN
[18,19], Knott [20], and Mesterton [21]
P Mean utility with dementia .60 y 0.54 0.03 N/L
Q Mean utility without dementia .60 y 0.84 0.04 O/M
Costs
R Costs of dementia per person per year, £ 28,507 8552 Luengo-Fernandez et al. [5]
S Cost of vitamins per day, £ 0.03 0.01 Retail price, from Lindens [22]
T Screening costs of tHcy per person, £ 10.00 3.00 Cost of screening kit
Abbreviations: QALYs, quality-adjusted life years; tHcy, total homocysteine.
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In 2014, there were 14.9 million people over 60 years in
the United Kingdom, of which approximately 1.3 million
had high level of tHcy. Because there was no available UK
estimate, we calculate the latter figure based on a US propor-
tion (i.e., 8.67%) of women over 60 years with high levels
(.13 mmol/L) of tHcy [15]. This proportion was almost 5
percentage points lower than the proportion of US males
with high tHcy [15]. This was a conservative assumption
because the levels in the UK are likely to be higher than in
the United States [7] (see Sensitivity analysis, below). To es-
timate the proportion of people with high tHcy who will
develop dementia, we used a population attributable risk per-
centage (PAR%) for high tHcy of 21.7% [6] and calculated
that 280,673 (51.3 million ! 21.7%) people will be at
risk of developing dementia due to tHcy and that 60,906
(280,673! 21.7%) of these will eventually develop demen-
tia in the course of their life.
2.2.2. Treatment effect
A study showed that lowering tHcy by 4 mmol/L (achiev-
able by B-vitamin treatment) would delay cognitive decline
by 10.9 months in 70-year-old patients with Alzheimer’s
disease [17]. We used this estimate as the treatment effectof B-vitamins in delaying dementia onset. In the VITACOG
trial, adherence to B-vitamin treatment was 78% [10].
Furthermore, we approximated that the mean age of people
over 60 years in the United Kingdom was 72 years in 2014
[18,19], whereas the mean age of people over 60 years
with dementia was 82 years in the same year [16]. Based
on the difference in these mean ages, we assumed that it
takes on average 10 years from screening tHcy in people
over 60 years to dementia onset. Taking into account the
above parameters, we estimated the delay in dementia onset
due to B-vitamin treatment by multiplying the B-vitamin ef-
fect on cognitive decline, treatment adherence, and years to
dementia.
2.2.3. Health outcomes
We calculated life expectancy of people .60 years and
total life years (LYs) based on UK Life Table 2012–2014
[19] and population estimates [18] for the general population
and based on estimates from Lewis et al. for people with de-
mentia [16]. QALYs for the general population were calcu-
lated based on the EQ5D utilities reported in the Health
Survey England [20]. QALYs for people with dementia
were calculated based on the number of people with mild,
moderate, or severe dementia [1] and the EQ5D utilities in
Table 2
Results from the univariate sensitivity analyses
Variable
Incremental
costs
Incremental
QALYs ICER
% More costly
& more effective
% Less costly
& more effective
People with high tHcy level: 19.8% instead
of 8.67%
2581 0.008 2£69,026 14 86
Treatment effect: 18 months delay in
cognitive decline instead of 10.9 months
21277 0.017 2£76,514 8 92
Screening costs: £20 instead of £10 2372 0.008 2£44,299 33 67
Screening costs: £5 instead of £10 2548 0.008 2£66,169 15 85
Treated population: 648,000 instead of 1.3
million
2367 0.008 2£44,304 34 66
Abbreviations: QALYs, quality-adjusted life years; tHcy, total homocysteine.
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estimated LYs and QALYs, we calculated the mean EQ5D
utility of people over 60 years with and without dementia.
2.2.4. Costs
The costs of dementia per patient per year were £28,507
based on a recent study [5], whereas the costs of a daily dose
of B-vitamins per patient (one tablet) were set at £0.03 based
on retail prices. Furthermore, the screening costs of tHcy per
patient were estimated to be £10, which includes the pur-
chase cost of a tHcy kit for typical clinical chemistry ana-
lyzers.2.3. Sensitivity analysis
Five univariate sensitivity analyses were performed to
investigate further the uncertainty in the cost-effectiveness
results (Table 2). In the first univariate sensitivity analysis,
we used 19.8%, instead of 8.67% in the main analysis, as
the proportion of people over 60 years with high levels of
tHcy. This proportion derives from the same study [15]
and may more realistically reflect the UK situation without
mandatory folic acid fortification, because it was based on
a 1991–1994 estimates which preceded the introduction of
mandatory folic acid fortification in the United States.Table 3
Cost-effectiveness results per treated patient (n 5 approximately 1.3 million)
Variable Mean
Intervention costs
Screening costs £126
Treatment costs £162
Total lifetime costs
Dementia lifetime costs £6891
Total costs with vitamins per treated person £7179
Total costs without vitamins per (un)treated person £7681
Incremental lifetime costs 2£502
Total lifetime QALYs
Total QALYs with vitamins per treated person 0.023
Total QALYs without vitamins per (un)treated person 0.015
Incremental QALYs per treated person 0.008
Incremental cost-effectiveness ratio 2£60,021
Abbreviation: QALYs, quality-adjusted life years.Furthermore, a delay of 18 months in global cognitive
decline (instead of 10.9 months in the main analysis) was
used in the second-sensitivity analysis based on the results
of the FACIT trial [9]. In the third-sensitivity analysis, we
assumed the screening costs to be £20 in case the tHcy test
would take place in GP practices without the use of auto-
mated kits. We also assumed the tHcy screening costs to
be £5 instead of £10 in the main analysis in a fourth sensi-
tivity analysis. This assumption seems realistic as tHcy tests
can be included in routinely ordered blood tests. Moreover,
assuming that health authorities would be able to support the
treatment for only half of the targeted population due to
budget constraints, we performed a fifth univariate sensi-
tivity analysis by changing the treated population from 1.3
million to 648,000 people.3. Results
3.1. Main results
The results of the cost-effectiveness analysis are listed in
Table 3. The total costs per treated person was £7179 and
consisted of £126 screening costs, £162 treatment costs,
and £6891 dementia-related costs. If the target group was
not treated with B-vitamins, the dementia-related costs
would be £7681. Hence, B-vitamins save on average £502Standard deviation Lower 95% CI Upper 95% CI
48 54 240
48 82 270
3820 1928 16,602
3820 2217 16,871
4200 2129 18,290
683 22302 245
0.018 0.002 0.070
0.012 0.001 0.045
0.007 0.001 0.026
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QALY gain per treated person (5 0.023 QALYs with treat-
ment 20.015 QALYs without treatment). As a result,
providing B-vitamin treatment dominates (i.e., more QALYs
and less costs) the strategy of not providing the treatment to
people over 60 years with high levels of tHcy. The estimated
ICER denotes that B-vitamins save £60,021 for an additional
QALY gained by the treated population. They are, therefore,
more effective and less costly than not providing treatment.
Fig. 1 illustrates the 10,000 ICERs plotted on the cost-
effectiveness plane and shows that 79% of themwere located
in the South-East quadrant indicating QALY gains and cost
savings, whereas the remaining 21% was located in the
North-East quadrant indicating QALY gains but at higher
costs.3.2. Univariate sensitivity analyses
The results from the univariate sensitivity analyses show
that B-vitamin treatment was very likely to be the dominant
strategy (i.e., more effective and less costly) in all cases. The
treatment appeared to lead to the highest QALY gains and
cost savings in the case of having a 18-month delay in global
cognitive decline due to B-vitamins. The costs savings were
lower when the screening costs were assumed to be £20 per
screened person and when only 640,000 eligible peoplewere
assumed to be treated with B-vitamins.4. Discussion
4.1. Stimulating debate and inspiring future research
Most trials of B-vitamin treatment against cognitive
decline were poorly designed by including subjects unlikely
to benefit during the trial period. In contrast, trials in high-
risk subjects, which have taken into account the baseline B
vitamin status, show a slowing of cognitive decline and of
atrophy in critical brain regions [7]. Therefore, our hypoth-
esis was that B-vitamins treatment is potentially a cost-
effective health population strategy for people with elevatedFig. 1. Cost-effectiveness plane.levels of tHcy. The results of this explorative analysis are
consistent with this hypothesis.
This argument may spark discussions on whether to
invest public resources to provide evidence about B-vitamin
treatment assuming that it is more cost-effective (or more
cost saving) than other prevention strategies [23,24], early
diagnosis strategies [25,26], disease modification
treatments [27], and currently used medication [28].
Although the results of this explorative study support our
postulate, we will not be able to know unless we have
more robust evidence. This evidence could only derive
from future studies with adequate study design and individ-
ual patient data. Appropriate dementia disease progression
models could also be used in these studies to provide robust
estimates about the lifetime costs and QALYs of treating pa-
tients with B-vitamins [29]. It should be also noted that B-vi-
tamins may be even more cost-effective if we look outside
dementia and incorporate the effect of these vitamins on
reducing cerebral atrophy [11], and consider the full costs
of mild cognitive impairment [30]. Establishing a screening
program for tHcy may have positive spill-over effects on the
prevention and treatment of other diseases, such as psychiat-
ric disorders [31], age-related macular degeneration [32],
and cardiovascular diseases, notably first stroke [33]. This
could increase the overall welfare gain of initiating tHcy
screening. Moreover, if tHcy screening became part of ordi-
nary blood testing ordered in GP practices and outpatient de-
partments for people over 60 years, the marginal screening
costs would be much lower than £10 assumed in this study.
This would increase the cost-effectiveness of B-vitamin
treatment. Perhaps, the most relevant question from the
perspective of public health authorities is who would bear
the costs of the B-vitamins. If the public health budget is
limited, individuals over 60 years with high levels of tHcy
would be asked to bear these costs. This may not be as con-
trary to the universal nature of NHS England as it sounds
considering that the lifetime treatment costs are only £162
per treated person. If public health authorities take up these
costs, the cost-effectiveness of B-vitamin treatment would
increase, assuming lower treatment costs due to strong pur-
chasing power.
We have followed a conservative approach in selecting
the input parameters in our model to explore the lowest po-
tential of B-vitamin treatment to be cost-effective. This was
the reason for using a treatment effect in delaying dementia
onset from an observational study in the main analysis and a
RCT (FACIT) on cognitive decline in the sensitivity anal-
ysis. Using the treatment, effect from other RCTs (e.g., the
VITAL trial) would have also shown B-vitamins to be
more cost-effective than our main analysis did.4.2. Conclusions
The results from the explorative cost-effectiveness anal-
ysis support the view that B-vitamins are potentially a
cost-saving prevention treatment for dementia to be used
A. Tsiachristas and A.D. Smith / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 156-161 161at population level. We anticipate that this provocative state-
ment will be debated by scientists, clinicians, and policy
makers and, we hope, eventually tested by the results of
future clinical trials.Acknowledgments
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